Responding to Criticism of ‘State Pharmaceutical Importation Programs Threaten Patients and Innovation
A recent article by Dr. Kristina M. L. Acri née Lybecker highlighted her research about the fiscal workability of state pharmaceutical importation programs from two aspects: Cost of counterfeit testing of products that have been handled by unregulated entities Because these medicines will be handled by unregulated entities, they need to be subjected to finished product testing using statistical sampling to ensure they’re genuine. The counterfeit pharmaceutical business is well established and has even involved licensed Canadian pharmacies and wholesalers, so no entity in Canada can be trusted, especially since we’ve previously had difficulties extraditing them for trial. Cost of adverse medical events due to...
Continue reading